In a letter to Robert Hooke in 1675, Isaac Newton made his most famous statement: “If I have seen further it is by standing on the shoulders of Giants”. This statement captures the essence of scientific progress. Progressive discoveries made by the most tenacious of us. To highlight Gynaecological Cancer Awareness Month, we will dig into the history of one of these giants, whose discovery changed the landscape of women's health forever.
Overcoming Early Setbacks
Dr. Georgios Papanikolaou, was a physician and researcher born in Greece in 1883. He moved to the United States in 1913. Initially struggling to make ends meet, the physician had to work in a carpet store. It took him a while until he was finally admitted to the staff at Cornell University’s medical college in New York City. But, Papanikolaou's early assignment was far from glamorous: he was tasked with studying the menstrual cycles of guinea pigs.
Over time, however, this seemingly mundane work turned into a deep understanding of cervical cells. Papanikolaou meticulously observed how these cells changed in shape according to hormonal fluctuations, eventually allowing him to predict the exact stage of a guinea pig's menstrual cycle. Building on this knowledge, he began applying his techniques to human subjects. By analyzing the morphology of cells from the human uterus, he could also predict the stages of the menstrual cycle. Despite a decade of obsessive research, these findings offered little practical benefit, as simpler methods already existed for this purpose.
Papanikolaou realized that the true potential of his work lay not in analyzing healthy cells but in identifying pathological conditions. He began collecting samples from women with various diseases. In the late 1920s, while examining cells from women with cervical cancer, he made a groundbreaking observation: cancerous cells could be detected in vaginal fluid. He published his results in 1928 in an article titled "New Cancer Diagnosis". However, the medical community criticized his findings and even mocked his suggestion. They already had better methods for detecting cervical cancer. After two decades of obsessively analyzing cervical cells, his two findings were useless. But his perseverance was not over.
Identifying cancer before symptoms even appear
Undeterred, Papanikolaou spent the next two decades refining his technique and gathering more evidence to support his hypothesis. His routine involved countless hours peering into a microscope, analyzing women’s vaginal smears with limited support. It wasn't until years later that he fully understood the profound implications of his work: his technique was not for detecting cancer but for identifying cancer before symptoms even appeared. Cervical cell analysis could detect cancerous cells years before any physical symptoms, allowing for much earlier intervention.
His research culminated in the 1943 publication of "Diagnosis of Uterine Cancer by the Vaginal Smear." This work provided the first comprehensive evidence that regular screening with the Pap test could detect cervical cancer at a pre-symptomatic stage, significantly improving the chances of successful treatment. Armed with this evidence, Papanikolaou convinced the National Cancer Institute to undertake the largest cancer prevention studies ever. 150,000 women from Shelby County, Tennessee, were screened using the Pap test. As a result, 555 cases of cervical cancer were detected, and more importantly, 557 asymptomatic women were found to have early-stage cervical cancer. The average age of these early-detected women was two decades younger than those diagnosed with advanced cancer, meaning the Pap test advanced their diagnosis by nearly 20 years, providing them with significantly better treatment outcomes.
Long-lasting Impact on Women's Health
The introduction of the Pap test marked a seismic shift in the fight against cervical cancer. Before its development, cervical cancer was one of the leading causes of cancer-related deaths among women, often diagnosed only when it was too late for effective treatment. The Pap test empowered women and healthcare providers by offering a simple, non-invasive method to detect abnormal cells early before they could develop into cancer. This early detection capability drastically reduced cervical cancer mortality rates and became a model for other cancer screening programs. However, the legacy of Georgios Papanikolaou’s discovery extends far beyond the Pap test itself. His work underscored the importance of early detection in cancer prevention, inspiring the introduction of other screening programs, such as the introduction of mammography.
As we reflect on the groundbreaking work of Dr. Georgios Papanikolaou and the life-saving potential of early detection, it's crucial to remember the importance of following recommended screening guidelines. Today, the Pap test is recommended every three years for women from 21 to 29, every five years for women from 29 to 65, and for women over 65, if they’re considered low-risk, screening may stop. Unfortunately, there are no screening tests for other GYN cancers, but genetic testing might help identify a predisposition to develop ovarian cancer. Regular screenings, such as the Pap test, OB-GYN visits, and genetic testing are vital tools of modern medicine to empower us to detect cancers early or even a predisposition to them. Early detection saves lives.
Written By Luis Guilherme
Book a FREE call with us to learn more about The After Cancer and get guidance on your journey.